Correction: Assessment of plasma lyso-Gb₃ for clinical monitoring of treatment response in migalastat-treated patients with Fabry disease

Affiliations

¹ Department of Medicine, Hôpital du Sacré Coeur, University of Montréal, Montréal, QC, Canada.
² Department of Medical Biochemistry, Leiden Institute of Chemistry, Leiden, Netherlands.
³ Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, QC, Canada.
⁴ Department of Clinical Nephroscience, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
⁵ Lysosomal Storage Disorders Unit, University College London, London, UK.
⁶ Amicus Therapeutics, Cranbury, NJ, USA.
⁷ Baylor Scott & White Research Institute, Dallas, TX, USA. Raphael.Schiffmann@BSWHealth.org.

Published Erratum

Daniel G Bichet et al. Genet Med. 2021 Jan.

. 2021 Jan;23(1):238.

doi: 10.1038/s41436-020-01041-5.

¹ Department of Medicine, Hôpital du Sacré Coeur, University of Montréal, Montréal, QC, Canada.
² Department of Medical Biochemistry, Leiden Institute of Chemistry, Leiden, Netherlands.
³ Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, QC, Canada.
⁴ Department of Clinical Nephroscience, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
⁵ Lysosomal Storage Disorders Unit, University College London, London, UK.
⁶ Amicus Therapeutics, Cranbury, NJ, USA.
⁷ Baylor Scott & White Research Institute, Dallas, TX, USA. Raphael.Schiffmann@BSWHealth.org.

No abstract available

Erratum for

Assessment of plasma lyso-Gb₃ for clinical monitoring of treatment response in migalastat-treated patients with Fabry disease.
Bichet DG, Aerts JM, Auray-Blais C, Maruyama H, Mehta AB, Skuban N, Krusinska E, Schiffmann R. Bichet DG, et al. Genet Med. 2021 Jan;23(1):192-201. doi: 10.1038/s41436-020-00968-z. Epub 2020 Sep 30. Genet Med. 2021. PMID: 32994552 Free PMC article.